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CASE REVIEW
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A 44 year old man with untreated HIV infection was referred
to the department of ophthalmology for routine screening of
ocular disease. He reported non-compliance with highly active
antiretroviral therapy (HAART) consisting of efavirenz,
tenofovir, and emtricitabine, and his CD4 count was below
50×106 cells/L. He had no ocular problems at the time of
presentation to his general practitioner.
His visual acuity was normal. Examination of the anterior
structures of both eyes was unremarkable. Examination of the
right eye identified a white annular edge of haemorrhagic
retinitis in a brushfire pattern (fig 1). The fundus of the left eye
looked normal.
Fig 1 Fundus photograph of the right eye on presentation
showing a white, annular leading edge of retinitis (white
arrows) associated with haemorrhage (blue arrow) in a
brushfire pattern.
Questions
1.What are the differential diagnoses for retinitis?
2.What is the diagnosis?
3.What is the most common cause of blindness in this
condition?




What are the differential diagnoses for
retinitis?
Short answer
Retinitis can be secondary to viral, bacterial, fungal, and
parasitic infections; autoimmune conditions; and cancer.
Discussion
The differential diagnoses include infections—viral (eg, herpes
simplex virus (HSV), herpes zoster virus (VZV),
cytomegalovirus (CMV)), bacterial (eg, syphilis and
tuberculosis), parasitic (eg, toxoplasmosis and Toxocara canis),
and fungal (eg, candida) entities. Autoimmune diseases such as
Behçet’s syndrome and cancers such as vitreoretinal lymphoma
should also be considered. A complete medical history, as well
as serological or intraocular fluid analysis (eg, polymerase chain
reaction, fungal smear) can help narrow the diagnosis.
2.




Our case is a striking example of CMV retinitis with a
“brushfire” pattern in an immunocompromised host. Although
the diagnosis was largely based on clinical examination,
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polymerase chain reaction of biopsied intraocular fluid
confirmed the presence of CMV.
Occasionally described as a “pizza pie,” “cheese and ketchup,”
or “brushfire” retinitis, CMV retinitis is the most common
opportunistic ocular infection in HIV/AIDS and other severely
immunocompromised states. CMV remains latent after primary
infection but is reactivated when cell mediated immunity is
severely impaired, as in HIV positive patients who are poorly
compliant with HAART.1The reactivated CMV can disseminate
throughout the body and seed any organ; the most common
target in patients with HIV is the eyes.1
CMV retinitis can be broadly categorised into two forms:
indolent and fulminant. The indolent form presents with granular
opacities in the peripheral retina and occasional associated
haemorrhages.2 3 The fulminant form manifests as confluent
areas of necrosis and prominent haemorrhages most commonly
starting along the major retinal vascular arcades.2 3 Few
inflammatory cells are present in the anterior or posterior
segments of the eye in both forms of the disease.
CMV retinitis is characterised by necrotic retinitis, which
progresses over months from an acute to a chronic stage.
Chronic inflammatory cells and both intranuclear and
intracytoplasmic inclusion bodies are seen throughout the active
margins of the lesions.4 With time, the cytoarchitecture of the
full thickness retina is destroyed, and this presents as atrophic
retina.5
Patients with CMV retinitis may be asymptomatic or they may
present with blurred or decreased vision, loss of peripheral or
central vision, and multiple floaters.6 Given that CMV retinitis
can be asymptomatic, it is important for primary care and
emergency physicians, infectious disease specialists, and
ophthalmologists to be aware of CMV retinitis and to be vigilant,
especially in patients with low CD4 counts, even in the absence
of presenting symptoms. Clinicians who care for
immunocompromised patients must therefore be able to
recognise CMV retinitis, especially in areas where access to
ophthalmology expertise is limited. One recent study showed
that a four day task oriented training workshop was sufficient
to train clinicians (non-ophthalmologists) working in HIV clinics
to do binocular indirect ophthalmoscopy for the diagnosis of
CMV retinitis.7
Although CMV retinitis is the most common ocular infection
in immunocompromised patients, other causes must be
considered. For example, cotton wool spots—infarctions of the
nerve fibre layer of the retina—are common in HIV retinopathy
but can be differentiated from early CMV retinitis by their
smaller size, more superior location, and lack of progression.8 9
Toxoplasmosis retinochoroiditis can also present with retinitis
similar to CMV infection, but the accompanying retinal
haemorrhage is usually less severe than that seen in untreated
CMV retinitis.10 Necrotising herpetic retinitis including acute
retinal necrosis (ARN) and progressive outer retinal necrosis
(PORN), which are linked to HSV and VZV, respectively, can
also occur in immunocompromised patients. PORN is
characterised by yellow-white infiltrates and often presents with
little or no vitritis, and its treatment (eg, intravitreal ganciclovir
or foscarnet) can be similar to that used for CMV retinitis.
However PORN can affect the macular region early on in the
disease process, whereas this region is often involved at a later
point in CMV retinitis.11 Overall, it is prudent to consider a
broad differential diagnosis for retinitis in immunocompromised
patients. If the clinical diagnosis remains uncertain, consider
evaluation of intraocular fluid by biopsy or diagnostic vitrectomy
with CMV specific polymerase chain reaction and histological
examination.12
3.
What is themost common cause of blindness
in this condition?
Short answer
CMV retinitis of the posterior pole.
Discussion
CMV infection can cause retinal necrosis, retinal detachment,
cataract, and optic atrophy, which can all lead to visual acuity
or visual field loss (or both).13 The three most common causes
of CMV associated blindness (less than 20/200 vision) are CMV
retinitis of the macular or optic nerve (posterior), cataract, and
retinal detachment, which account for ~55%, ~25%, and ~15%
of cases, respectively.14
Because the macula is responsible for the detection of fine
details (vision better than 20/200) and the optic nerve transmits
all visual information from the retina to the brain, it is not
surprising that CMV retinitis involving these structures can
cause blindness. In some cases, CMV retinitis affects the
peripheral retina first, and in this situation the risk of blindness
can be decreased by starting treatment before the macula or
optic nerve is affected.14 Cataract often occurs after immune
recovery (>100×106 cells/L), and because it is less common
when CD4 cell counts are low it is thought to have an
inflammatory component.14 In addition to cataract, immune
recovery can be associated with symptoms of posterior uveitis,
such as cystoid macular oedema, vitritis, and epiretinal
membrane formation, which can also cause vision loss, although
they are not such common causes of vision loss as retinitis of
the macular or optic nerve, cataract, and retinal detachment.14
Although retinal detachment is only the third most common
cause of CMV related blindness, it is an ominous risk factor: it
portends blindness to a greater degree than involvement of the
macula or optic nerve and cataract.14 Retinal detachment is
usually caused by retinal holes at the junction of the affected
atrophic retina and the normal retina. This is precipitated by
traction of the vitreous on the underlying retina.15 The reported
incidence of retinal detachment in patients with CMV retinitis
is 33-50% per eye per year.16-18 One retrospective study found
that adherence to HAART in patients with HIV and a diagnosis
of CMV retinitis statistically significantly reduces the risk of
progression to retinal detachment.19 This is probably because
the immune response reduces CMV replication, which may
suppress retinitis activity and prevent progression of the retinal
lesions. This is consistent with other studies showing that larger
lesion size is a known risk factor for development of retinal
detachment.16 18
Since the introduction of HAART, the incidence of CMV
retinitis has plummeted in developed countries. However, data
from the Longitudinal Study of the Ocular Complications of
AIDS (LSOCA) show that even though CMV retinitis related
ocular complications and overall mortality have decreased,
patients with this condition still experience CMV related vision
loss such as retinal detachment and cataract, as well as death at
five year follow-up.14 20
4.
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What are the available treatments and
follow-up recommendations?
Short answer
Intravenous ganciclovir, the oral prodrug valganciclovir,
intravenous foscarnet, intravenous cidofovir, intravitreal
injections of ganciclovir or foscarnet, or the ganciclovir
intraocular implant (not currently available).
Discussion
The treatment of CMV retinitis includes systemic or local
(intravitreal) administration of the anti-CMV drugs listed above.
Studies demonstrating the efficacy of these drugs were largely
performed before the introduction of HAART.21 22 The overall
finding from these studies is that intraocular localised therapy
with the ganciclovir implant controls retinitis better than
systemic ganciclovir alone, but that systemic treatment prevents
dissemination (spread to second eye in uniocular disease or
visceral dissemination) better than intraocular implant therapy
alone.23-25
LSOCA showed that even with the introduction of HAART,
anti-CMV systemic drugs decrease the risk of mortality and
visceral dissemination and, in unilateral ocular disease, decrease
the risk of dissemination to the other eye.25 Overall, the study
authors recommended instituting systemic treatment in patients
with newly diagnosed CMV retinitis regardless of whether
concomitant intraocular (direct injection into the vitreous)
therapy is given, and that treatment should be continued at least
until the CD4 count has returned to ≥100×106 cells/L cells for
six months or more.25 26
Before HAART was introduced, 41.9%, 26.3%, and 14.7% of
patients with baseline CD4 counts of 0-50×106 cells/L,
51-100×106 cells/L, and 101-250×106 cells/L, respectively,
developed CMV retinitis over about two years.27 Although
HAART has reduced the incidence of CMV retinitis by about
75%,14-28 it is still one of the most common opportunistic
infections in patients with AIDS. With the introduction of
HAART, the rate of progression to retinitis has decreased from
3 per patient year to 0.10 per patient year. For the subset of
patients with CD4 cells ≥100×106 cells/L progression has
decrease further to 0.06 per patient year (CD4 count
199-299×106 cells/L) and 0.02 per patient year (CD4 count
≥200×106 cells/L). Thus the rate of progression to retinitis is
not zero, and patients with CD4 counts ≤100×106 cells/L can
relapse. Indeed, LSOCA investigators recommend dilated
ophthalmic examination every three months in patients with a
history of CMV retinitis and a CD4 count of ≤100×106 cells/L
even when systemic anti-CMV therapy has been
discontinued.20 28
CMV retinitis can cause blindness so requires urgent treatment,
with referral to ophthalmology and infectious disease
consultants. Hospital admission should be considered if
compliance remains uncertain.
Patient outcome
After diagnosis, the patient was started on HAART and oral
valganciclovir. In addition to regular follow-up for his retina
care, he regularly visited an infectious disease specialist. Oral
valganciclovir was stopped nearly a year after his initial visit
when he achieved a CD4 count ≥100×106 cells/L, which was
sustained during the follow-up period (two years after his first
ophthalmic examination). During this time, the CMV retinitis
evolved from a haemorrhagic form to an inactive retinal scar.
The haemorrhages gradually resolved over two years, a
subretinal band formed, and a demarcation line (the boundary
between viable and scarred necrotic retina) appeared (fig 2).
His retinitis has not recurred.
Fig 2 Fundus photographs of the right eye during two years
of treatment. The right eye was examined after initiation
of highly active antiretroviral therapy and oral ganciclovir.
The retinitis (white arrows) and haemorrhages (blue
arrows) resolved over one week (A), six weeks (B), and at
two years (C). A subretinal band formed at six weeks (B;
black arrowhead), and persisted at two years (C, blue
arrowhead). At two years (C), a demarcation line (white
arrows: boundary between viable and scarred, necrotic
retina) formed in the place of the leading edge of the
previous retinitis (A and B; white arrows)
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